Weekly BI 836880 in Patients With Advanced Solid Tumors
NCT02689505
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
BI 836880
Sponsor
Boehringer Ingelheim